Fox Run Management L.L.C. Acquires New Stake in Puma Biotechnology Inc (PBYI)

Fox Run Management L.L.C. acquired a new position in shares of Puma Biotechnology Inc (NASDAQ:PBYI) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,063 shares of the biopharmaceutical company’s stock, valued at approximately $553,000.

Several other hedge funds also recently modified their holdings of the company. State of Wisconsin Investment Board increased its position in shares of Puma Biotechnology by 3.8% during the second quarter. State of Wisconsin Investment Board now owns 29,700 shares of the biopharmaceutical company’s stock worth $1,757,000 after acquiring an additional 1,100 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. grew its position in Puma Biotechnology by 307.1% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,547 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 1,167 shares in the last quarter. Creative Planning grew its position in Puma Biotechnology by 30.1% in the second quarter. Creative Planning now owns 5,129 shares of the biopharmaceutical company’s stock valued at $303,000 after purchasing an additional 1,188 shares in the last quarter. Xact Kapitalforvaltning AB grew its position in Puma Biotechnology by 50.7% in the first quarter. Xact Kapitalforvaltning AB now owns 4,458 shares of the biopharmaceutical company’s stock valued at $303,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Virginia Retirement Systems ET AL grew its position in Puma Biotechnology by 7.1% in the second quarter. Virginia Retirement Systems ET AL now owns 22,600 shares of the biopharmaceutical company’s stock valued at $1,337,000 after purchasing an additional 1,500 shares in the last quarter. 92.37% of the stock is owned by institutional investors.

In other news, insider Richard Paul Bryce sold 1,836 shares of Puma Biotechnology stock in a transaction dated Friday, July 20th. The shares were sold at an average price of $51.95, for a total value of $95,380.20. Following the completion of the transaction, the insider now owns 32,543 shares of the company’s stock, valued at approximately $1,690,608.85. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Alan H. Auerbach sold 12,520 shares of Puma Biotechnology stock in a transaction dated Friday, July 20th. The shares were sold at an average price of $52.00, for a total transaction of $651,040.00. Following the completion of the transaction, the chief executive officer now directly owns 4,179,061 shares of the company’s stock, valued at approximately $217,311,172. The disclosure for this sale can be found here. Company insiders own 21.50% of the company’s stock.

PBYI has been the subject of a number of analyst reports. Cantor Fitzgerald initiated coverage on shares of Puma Biotechnology in a research report on Monday, October 1st. They issued an “overweight” rating and a $75.00 target price for the company. BidaskClub downgraded shares of Puma Biotechnology from a “sell” rating to a “strong sell” rating in a research report on Thursday, September 20th. JPMorgan Chase & Co. raised their target price on shares of Puma Biotechnology from $80.00 to $83.00 and gave the company a “buy” rating in a research report on Friday, August 10th. Citigroup decreased their target price on shares of Puma Biotechnology from $164.00 to $151.00 and set a “buy” rating for the company in a research report on Tuesday, September 18th. Finally, Guggenheim initiated coverage on shares of Puma Biotechnology in a research report on Monday, September 17th. They issued a “buy” rating for the company. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $93.17.

Shares of PBYI opened at $44.56 on Monday. Puma Biotechnology Inc has a one year low of $40.45 and a one year high of $136.90. The stock has a market capitalization of $1.74 billion, a PE ratio of -5.68 and a beta of -0.23. The company has a quick ratio of 2.64, a current ratio of 2.68 and a debt-to-equity ratio of 3.14.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.09. Puma Biotechnology had a negative net margin of 146.27% and a negative return on equity of 367.92%. The company had revenue of $50.80 million during the quarter, compared to the consensus estimate of $45.67 million. During the same quarter last year, the firm posted ($1.38) EPS. On average, research analysts forecast that Puma Biotechnology Inc will post -3.86 earnings per share for the current fiscal year.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)).

Featured Article: Insider Trading – What You Need to Know

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NASDAQ:PBYI).

Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply